ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

07 8 2025 03:59:33 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

29 7 2025 13:01:47 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Leadership Transition

28 7 2025 05:45:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

30 6 2025 06:31:48 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

26 6 2025 13:01:27 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

23 6 2025 03:59:36 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

02 6 2025 03:59:53 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

28 5 2025 06:20:15 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

09 5 2025 04:00:19 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

08 5 2025 03:50:51 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

29 4 2025 04:00:32 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

22 4 2025 03:59:08 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

04 3 2025 04:00:05 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

27 2 2025 03:59:55 提供 Nasdaq GlobeNewswire

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

12 2 2025 03:50:01 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

30 1 2025 13:01:21 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06 1 2025 13:30:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03 12 2024 13:30:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 11 2024 13:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

19 11 2024 06:45:01 提供 NetDania Notify